** Shares of gene therapy co Sarepta Therapeutics SRPT.O fall 10.3% to $122.96 premarket

** Co reports Q1 revenue of $102 million for its muscle disorder gene therapy Elevidys, compared to $375 million for the same period of 2025

** SRPT says this reflects a lower volume of Elevidys sales due to an updated label that only includes patients who can walk for treatment

** Last year, the FDA limited the use of muscle disorder gene therapy Elevidys to patients who can walk after safety concerns and patient deaths prompted FDA scrutiny and a temporary pause in shipments

** Co reports quarterly revenue of $730.8 million, down $14.1 million from the prior year

** SRPT says the decrease is partially offset by an increase in collaboration revenues

** Up to last close, stock up 7% YTD